Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How ANVS compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 101.1% | — | +0.0 pp | |
| LTM Dec 2025 | 76.0% | +3.7 pp | +85.4 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ANVS) | 88.6% | +3.7 pp | +42.7 pp | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.48M | 16.52M | 38.79M | 20M | 25.22M |
| Selling, General & Admin | 6.06M | 9M | 6.24M | 6.7M | 4.48M |
| Operating Expenses | 14.54M | 25.51M | 45.04M | 26.69M | 29.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (14.5M) | (25.33M) | (56.2M) | (22.74M) | (28.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.54M) | (25.51M) | (45.04M) | (26.69M) | (29.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13.34K | 182.71K | 667.9K | 331.85K | 699.06K |
| Interest Expense | 0 | 0 | 0 | 1.85M | 0 |
| Other Income / Expenses | 50.09K | 182.71K | (11.17M) | 2.1M | 841.06K |
| Income Before Tax | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.90) | (3.10) | (6.23) | (2,018.50) | (1.40) |
| EPS (Diluted) | (1.90) | (3.10) | (6.23) | (2,009.77) | (1.40) |
| Weighted Avg Shares | 7.63M | 8.16M | 9.02M | 12.18M | 20.55M |
| Weighted Avg Shares (Diluted) | 7.63M | 8.16M | 9.02M | 12.24M | 20.55M |
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.